跳至主要内容
临床试验/ITMCTR2100004548
ITMCTR2100004548招募中4 期

Post marketing safety evaluation of Fufang Congrong Yizhi Capsule

Xiyuan Hospital of China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational study

入排标准

年龄范围
50 至 80(—)
性别
All

入选标准

  • (1) All the inpatients and / or outpatients who used compound Cistanche yizhi capsule at least once, regardless of the duration of medication, were regarded as the monitoring population;
  • (2) Outpatients and inpatients with vascular dementia (may have comorbidities);
  • (3) The patient or his / her legal representative informed the research purpose, method and possible risks in a clear and normal mental state, did not interfere with the decision of the patient or his / her legal agent, agreed to participate in the study, and signed the informed consent.

排除标准

  • (1) Loose stool;
  • (2) Patients with serious diseases such as heart, brain, liver, kidney or hematopoietic system;
  • (3) Abnormal liver and kidney function, abnormal ECG with clinical significance;
  • (4) Known to be allergic to the components of compound Congrong yizhi capsule;
  • (5) Patients are participating in other clinical trials.

研究者

相似试验